Table 4 Recommendations of intravesical therapy for low and intermediate risk patientsa
Guideline ID | Low risk | Intermediate risk | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Induction | Induction | Maintenance | |||||||||
Not be recommended | Be recommended | Course of treatment | Be recommended | Course of treatment | |||||||
SOR/LOE | Chemotherapy | BCG | Chemotherapy | BCG | Chemotherapy | BCG | |||||
SOR/LOE | SOR/LOE | Course | SOR/LOE | SOR/LOE | SOR/LOE | Course | SOR/LOE | Course | SOR/LOE | ||
ESMO, 2014 [8] | −/− | −/− | −/− | – | −/− | −/− | −/− | – | −/− | – | −/− |
NICE, 2015 [9]b | −/− | A/high-low | −/− | At least 6 doses | A/high-low | −/− | −/− | – | −/− | – | −/− |
CUA, 2015 [10] | −/− | B/− | B/− | – | −/− | B/− | B/− | 1 years | B/− | – | −/− |
AUA/SUO, 2016 [3] | Moderate/C | Moderate/B | Moderate/B | 6 weeks | Moderate/B | Conditional/C | Moderate/C | – | −/− | 1 year | Moderate/C |
JUA, 2016 [11] | −/− | −/− | −/− | – | −/− | −/− | −/− | – | −/− | – | −/− |
EAU, 2018 [12] | −/− | −/− | Strong/1a-3 | – | −/− | Strong/1a-3 | Strong/1a-3 | ≤ 1 years | Weak/3 | Full dose, 1 year Three-weekly instillations at 3, 6 and 12 months | Strong/1a-1b |
ICUD/SIU, 2018 [13] | A/1a | B/2a | A/1a | – | −/− | B/2a | A/1a | 6-12 months | B/2a | Full dose, 1 year | A/1a |
CRHA/CPAM, 2018 [14] | B/1a | A/1a | B/1a-1b | Weekly for 4–8 weeks | A/1a | A/1a | A/1a | Monthly for 6–10 months | A/1a | Low dose | B/1a-1b |
1–3 years | B/1b | ||||||||||
NCCN, 2019 [15]c | −/− | B/2A | A/2A | Initiated 3–4 weeks after TURBT | B/2A | B/2A | A/2A | – | −/− | 1 year | B/2A |
Weekly for 6 weeks | B/2A | ||||||||||